**Poster Discussion Sessions**
(Available on demand from Friday, May 29 8AM ET/7AM CST)

**Session: Breast Cancer – Metastatic**
Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).

**Authors** Minetta C. Liu...Gini F. Fleming...Amylou C. Dueck

**Abstract** 1016 • 101

**Session: Genitourinary Cancer – Kidney and Bladder**
Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.

**Authors** Jonathan E. Rosenberg...Randy F. Sweis.

**Abstract** 5014 • 83

**Session: Genitourinary Cancer – Prostate, Testicular, and Penile**
TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).

**Authors** Samuel R. Denmeade...Russell Zelig Szmulewitz...Emmanuel S. Antonarakis.

**Abstract** 5517 • 98

**Session: Pediatric Oncology**
Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403.

**Authors** Jennifer Lynn McNeer...Richard A. Larson...Wendy Stock...Elizabeth A. Raetz.

**Abstract** 10520 • 105

**Session: Pediatric Oncology**
Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.

**Authors** Ami Vijay Desai...Susan Lerner Cohn...Alice L. Yu.

**Abstract** 10523 • 410

**Session: Head and Neck Cancer**
Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

**Authors** Roger B. Cohen...Alexander T. Pearson...Jerome Fayette.

**Abstract** 6516 • 177

**Session: Hematologica Malignancies – Plasma Cell Dyscrasia**
Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT

**Authors** Benjamin Avi Derman...Jagoda Jasielec, Andrzej J. Jakubowiak.

**Abstract** 8513 • 413

**Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant**
Long-term survivors and gilteritinib safety beyond one year in FL73-mutated R/R AML: ADMIRAL trial follow-up.

**Authors** Alexander E. Perl...Richard A. Larson...Erkut Bahceci.

**Abstract** 7514 • 287
Symposia Oral Abstracts
(Available on demand from Friday, May 29 8AM ET/7AM CST)

Session: Breast Cancer—Local/Regional/Adjuvant
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Authors Cynthia X. Ma...Olwen Mary Hahn...Matthew James Ellis.
Abstract 504

Session: Breast Cancer—Metastatic
Tbcrc 048: a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in dna damage response (DDR) pathway genes (olaparib expanded).
Authors Nadine M. Tung...Rita Nanda...Judy Ellen Garber.
Abstract 1002

Session: Breast Cancer – Local/Regional/Adjuvant
Steps Forward and Lessons Learned: Using Biomarkers to Guide Targeted Therapies in Breast Cancer, The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium supported by the Breast Cancer Research Foundation*.
A multiparameter classifier to predict response to lapatinib plus trastuzumab (lt) without chemotherapy in her2+ breast cancer (bc).
Authors Jamunarani Veeraraghavan...Rita Nanda...Mothaffar F. Rimawi.
Abstract 1011

Session: Central Nervous System Tumors
Randomized phase ii study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary cns lymphoma (PCNSL).
Authors Antonio Marcilio...Theodore Karrison...Minesh P. Mehta.
Abstract 2501

Session: Hematologic Malignancies—Plasma Cell Dyscrasia
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Authors Sham Mailankody, Andrzej J. Jakubowiak...Kuan Wong.
Abstract 8504

Session: Hematologic Malignancies—Plasma Cell Dyscrasia
Update of CARTITUDE-I: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Authors Jesus G. Berdeja...Andrzej J. Jakubowiak, Sundar Jagannath.
Abstract 8505

Session: Learning from the Biology: Advances in Endometrial and Ovarian Cancer
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
Authors Stephanie Lheureux...Gini F. Fleming.
Abstract 6010

Session: Developmental Therapeutics—Immunotherapy
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
Authors Jason J. Luke...Hedy L. Kindler...George Blumenschein.
Abstract 3004
Symposia Oral Abstracts (Continued)

Session: Melanoma/Skin Cancers
Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBO) immediately following progression on pd1 ab in melanoma (MEL) in a phase ii trial.
Authors Daniel Olson...Theodore Karrison...Thomas Gajewski. Nikhil I. Khushalani.
Abstract 10004

Session: Pediatric Oncology I
Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.
Authors Steven G. DuBois...Susan Lerner Cohn...Katherine K. Matthay.
Abstract 10500

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.
Authors Patrick M. Forde...Hedy L. Kindler...Suresh S. Ramalingam.
Abstract 9003

Session: Drug Development for Rare Mutations: The Opportunity to Unite and Conquer!
Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.
Authors Ami Vijay Desai...Elizabeth Fox.
Abstract 107

Session: MET Mutations: The Meat of the Matter
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14).
Authors D. Ross Camidge...Daniel V.T. Catenacci...Enriqueta Felip.
Abstract 9510

Session: Genitourinary Cancer—Kidney and Bladder
Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).
Authors Rana R. McKay...Walter Michael Stadler...Toni K. Choueiri.
Abstract 5005

Session: Genitourinary Cancer—Kidney and Bladder
Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.
Authors Matt D. Galsky...Peter H. O'Donnell...Sanjeev Mariathasan.
Abstract 5011

Session: Genitourinary Cancer—Kidney and Bladder
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
Authors Maha H. A. Hussain...Peter H. O’Donnell...Joaquim Bellmunt.
Abstract 5000
Publication Only

Session: Publication Only: Sarcoma
Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning.
Authors Ari Rosenberg, Alexander T. Pearson.
Abstract e23529

Session: Publication Only: Symptoms and Survivorship
Evaluation of prescribing practices of denosumab and zoledronic acid in breast and prostate cancer patients at University of Chicago Medicine.
Authors Heng Yang, Walter Michael Stadler.
Abstract e24144

Session: Publication Only: Care Delivery and Regulatory Policy
Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic.
Authors Amin Virani, Andrzej J. Jakubowiak, Jagoda Jasielec, Sandeep Parsad.
Abstract e14030

Session: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile
Expansion of germline genetic testing criteria for prostate cancer yields findings across all stages of disease.
Authors Sarah M. Nielsen, Russell Zelig Szmulowitz, Edward D. Esplin.
Abstract e17615

Session: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).
Authors Lawrence Howard Schwartz, Hedy L. Kindler, Talia Golan.
Abstract e16800

Session: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.
Authors Amy S. Ruppert, Richard A. Larson, Jennifer Ann Woyach.
Abstract e20004

Posters
(Available on demand from Friday, May 29 8AM ET/7AM CST)

Session: Improving cancer pain control: Potential impact of CYP2D6 pharmacogenomic (PGx) testing in oncology (Onc) patients.
Symptoms and Survivorship
Author(s) Natalie Reizine, Mark J. Ratain, Peter H. O’Donnell.
Abstract / POSTER 12089 • 377

Session: Using sequential next-generation sequencing assays to identify germline cancer predisposition variants.
Cancer Prevention, Risk Reduction, and Genetics
Author(s) Ira Lignugaris Kraft, Jeremy Segal, Lucy A. Godley.
Abstract / POSTER 1581 • 73
Posters (Continued)

Session: Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial.
Head and Neck Cancer
Author(s) Ari Rosenberg, Nishant Agrawal, Alexander T. Pearson...Elizabeth A. Blair...Mark W. Lingen, Daniel J. Haraf, Everett E. Vokes.
Abstract / POSTER 6575 • 236

Session: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Daniel V.T. Catenacci...Chih-Yi Liao...John Hart...Yuan Ji. Theodore Karrison, Blase N. Polite, Hedy L. Kindler.
Abstract / POSTER 4561 • 169

Session: Randomized phase I trial to evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and stereotactic body Radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study).
Lung Cancer—Non-Small Cell Metastatic
Author(s) Jyoti D. Patel, Christine M. Bestvina. Theodore Karrison...Philip C. Hoffman. Sean P. Pitroda, Everett E. Vokes, Steven J. Chmura.
Abstract / POSTER 9616 • 382

Session: Morphologic and molecular analysis of early-onset gastroesophageal adenocarcinomas.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Namrata Setia...Sonia Kupfer. John Hart. Daniel V.T. Catenacci.
Abstract / POSTER 4547 • 155

Session: Assessment of FcgRIIIA single nucleotide polymorphisms (SNPs) on the efficacy of IgG1 monoclonal antibodies (mAbs) in PANGEA study patients (pts) with advanced gastroesophageal adenocarcinoma (aGEA).
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Anthony Serritella...Daniel V.T. Catenacci.
Abstract / POSTER 4526 • 134

Session: Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response.
Developmental Therapeutics—Immunotherapy
Author(s) Pankti Reid...Thomas Gajewski.
Abstract / POSTER 3066 • 130

Session: Detection of somatic mutations in saliva of patients with oral cavity squamous cell carcinoma.
Head and Neck Cancer
Author(s) Evgeny Izumchenko...Mark W. Lingen. Nishant Agrawal.
Abstract / POSTER 6562 • 223

Session: Evaluation of spatiotemporal heterogeneity of PDL1 expression in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Katherine I. Zhou...Daniel V.T. Catenacci.
Abstract / POSTER 4528 • 136

Session: Evaluation of spatiotemporal heterogeneity of tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Katherine I. Zhou...Daniel V.T. Catenacci.
Abstract / POSTER 4546 • 154
Posters (Continued II)

Session: Machine learning guided adjuvant treatment of head and neck cancer.
Head and Neck Cancer
Author(s) Frederick Howard...Michael T. Spiotto, Alexander T. Pearson.
Abstract / POSTER 6567 • 228

Pediatric Oncology
Author(s) Matthew R. Trendowski...M. Eileen Dolan.
Abstract / POSTER 10550 • 437

Session: Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.
Developmental Therapeutics—Immunotherapy
Author(s) Colette Shen...Alexander T. Pearson...Tanguy Y. Seiwert.
Abstract / POSTER TPS3173 • 237

Session: Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.
Gynecologic Cancer
Author(s) Daniela Matei...John William Moroney, Gini F. Fleming...Bin Zhang.
Abstract / POSTER 6025 • 196

Session: Outcome in patients with refractory high-risk neuroblastoma.
Pediatric Oncology
Author(s) Amir Bari Siddiqui...Susan Lerner Cohn. Ami Vijay Desai.
Abstract / POSTER 10537 • 424

Session: Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.
Developmental Therapeutics—Immunotherapy
Author(s) E. Antonio Chiocca...Bakhtiar Yamini...Laurence JN Cooper.
Abstract / POSTER 3040 • 104

Session: SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Author(s) Amita Patnaik, Hedy L. Kindler...Ani Sarkis Balmanoukian.
Abstract / POSTER TPS3652 • 382

Session: Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.
Breast Cancer—Local/Regional/Adjuvant
Author(s) Hope S. Rugo...Rita Nanda...Binghe Xu.
Abstract / POSTER TPS599 • 91

Session: Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Andrew L. Coveler...Hedy L. Kindler...Martin Gutierrez.
Abstract / POSTER TPS4671 • 279
Posters (Continued III)

Session: PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).
Gynecologic Cancer
Author(s) Carol Aghajanian...Gini F. Fleming...Robert L. Coleman.
Abstract / POSTER 6077 • 248

Session: SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.
Breast Cancer—Metastatic
Author(s) Heather Christine Beckwith...Rita Nanda...Howard A. Burris III.
Abstract / POSTER TPS1104 • 189

Session: ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Author(s) Jacob Sands...Everett E. Vokes...Tom Stinchcombe.
Abstract / POSTER TPS9077 • 270

Session: Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study.
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Samuel J Klempner...Daniel V.T. Catenacci...Atsushi Ohtsu.
Abstract / POSTER 4543 • 151

Session: Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.
Developmental Therapeutics—Immunotherapy
Author(s) Andrew Greenstein...Gini F. Fleming...Stacie Peacock Shepherd.
Abstract / POSTER 3091 • 155

Session: POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Hyun Kyoo Yoo, Hedy L. Kindler...Talia Golan.
Abstract / POSTER 4626 • 234

Session: Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s) Talia Golan, Hedy L. Kindler...Yu-Zhen Liu.
Abstract / POSTER 4621 • 229

Session: Abbreviated geriatric assessment (GA) in new oncology patients and its association with early death. Symptoms and Survivorship
Author(s) Michael Maranzano...Blase N. Polite, Selina Lai-ming Chow.
Abstract / POSTER 12035 • 323

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Author(s) Benedito A. Carneiro, Christine M. Bestvina...Kyriakos P. Papadopoulos.
Abstract / POSTER TPS3649 • 379
Posters (Continued IV)

Session: **Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2-positive metastatic pancreatic cancer (mPC).**
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
**Author(s)** Wungki Park...Hedy L. Kindler.
**Abstract / POSTER** TPS4667 • 275

Session: **Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.**
Developmental Therapeutics—Immunotherapy
**Author(s)** John D. Powderly...Daniel V.T. Catenacci...William Ho.
**Abstract / POSTER** TPS3163 • 227

Session: **KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).**
Breast Cancer—Local/Regional/Adjuvant
**Author(s)** Hope S. Rugo...Rita Nanda...Vassiliki Karantza.
**Abstract / POSTER** TPS596 • 88

Session: **Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.**
Genitourinary Cancer—Prostate, Testicular, and Penile
**Author(s)** Neal D. Shore...Russell Zelig Szmulewitz...Arnulf Stenzl.
**Abstract / POSTER** 5547 • 128

Session: **CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).**
Breast Cancer—Local/Regional/Adjuvant
**Author(s)** Valentina Boni...Randy F. Sweis...Funda Meric-Bernstam.
**Abstract / POSTER** 526 • 18

Session: **Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial.**
Breast Cancer—Metastatic
**Author(s)** Neelima Vidula, Rita Nanda...Hope S. Rugo.
**Abstract / POSTER** 5114 • 199

Session: **KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.**
Developmental Therapeutics—Immunotherapy
**Author(s)** Kedar Kirtane...Michael Russell Bishop...A. Scott Jung.
**Abstract / POSTER** 3149 • 213

Session: **Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2- advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.**
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
**Author(s)** Manish A. Shah...Daniel Catenacci...Rui-hua Xu.
**Abstract / POSTER** 4648 • 256
Posters (Continued V)

Session: Phase Ib trial combining rapid determination of drug-drug interaction (DDI) followed by a dose finding period to assess safety and preliminary efficacy of fimepinostat plus venetoclax in patients with aggressive B-cell lymphoma.
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Author(s) Tycel Jovelle Phillips...Sonali M. Smith...Connie Lee Batlevi.
Abstract / POSTER 8056 • 389

Session: Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.
Breast Cancer—Metastatic
Author(s) Patricia LoRusso...Rita Nanda...Kurt A. Schalper.
Abstract / POSTER TPS1102 • 187

Session: Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).
Genitourinary Cancer—Prostate, Testicular, and Penile
Author(s) William Kevin Kelly...Russell Zelig Szmulewitz...Guru Sonpavde.
Abstract / POSTER 5540 • 121

Session: Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).
Lung Cancer—Non-Small Cell Metastatic
Author(s) Mary Weber Redman...Everett E. Vokes...Roy S. Herbst.
Abstract / POSTER 9576 • 342

Session: Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.
Developmental Therapeutics—Immunotherapy
Author(s) Charles G. Drake...Chih-Yi Liao...Daniel V.T. Catenacci.
Abstract / POSTER 3137 • 201

Session: Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Author(s) Taofeek Kunle Owonikoko...Everett E. Vokes...Marie-Anne Damiette Smit.
Abstract / POSTER TPS9080 • 273

Session: AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Author(s) Helen J. Ross...Everett E. Vokes, Tom Stinchcombe.
Abstract / POSTER 9045 • 238